Betjes Michiel G H, Habib Sayed M, Boeschoten Els W, Hemke Aline C, Struijk Dick G, Westerhuis Ralph, Abrahams Alferso C, Korte Mario R
Erasmus Medical Center, Department of Nephrology & Transplantation, Erasmus Medical Center, Rotterdam, Netherlands
Erasmus Medical Center, Department of Nephrology & Transplantation, Erasmus Medical Center, Rotterdam, Netherlands.
Perit Dial Int. 2017 Mar-Apr;37(2):230-234. doi: 10.3747/pdi.2016.00109.
The Dutch Encapsulating Peritoneal Sclerosis (EPS) Registry was started in 2009. Cases were identified by contacting all Dutch nephrologists twice yearly. The predefined criteria for EPS allowed for inclusion of patients with diagnosed and suspected EPS. Cases registered between January 2009 and January 2015 were analyzed with follow-up until September 2015. Fifty-three EPS cases were identified, of which 28.3% were post-transplantation EPS cases. Fourteen patients were initially categorized as suspected EPS, of whom 13 developed EPS. A remarkable 6-fold decrease in the yearly incidence of EPS was observed, from 0.85% in 2009 to 0.14% in 2014. This decrease could not be explained by a decrease in the number of PD patients or average duration of PD treatment in this period. Two-year survival of EPS patients was 52%. The use of tamoxifen and surgical interventions increased significantly over the years. Tamoxifen-treated cases showed a trend to better patient survival and post-transplantation EPS had a significantly favorable outcome. In conclusion, the incidence of EPS has declined significantly in the Netherlands from 2009 to 2014.
荷兰包裹性腹膜硬化症(EPS)登记处始建于2009年。通过每年两次联系所有荷兰肾脏病学家来确定病例。EPS的预定义标准允许纳入已确诊和疑似EPS的患者。对2009年1月至2015年1月登记的病例进行分析,并随访至2015年9月。共确定了53例EPS病例,其中28.3%为移植后EPS病例。14例患者最初被归类为疑似EPS,其中13例发展为EPS。观察到EPS的年发病率显著下降了6倍,从2009年的0.85%降至2014年的0.14%。这一下降无法用该时期腹膜透析患者数量的减少或腹膜透析治疗的平均持续时间来解释。EPS患者的两年生存率为52%。多年来,他莫昔芬的使用和手术干预显著增加。接受他莫昔芬治疗的病例显示患者生存率有提高的趋势,移植后EPS有显著良好的结果。总之,2009年至2014年期间,荷兰EPS的发病率显著下降。